stonks4u
Sign up free
SKYE logo

SKYE Skye Bioscience, Inc.

NASDAQ · Biotechnology · Healthcare

$0.50
-0.04 (-7.30%)

Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was…

Market Cap: $17.62Mskyebioscience.com

Price (90d)

No price history yet — the daily price refresh runs once a day.

Signal Score (90d)

90
90
Aug 14Aug 14

Quote

Day Range
$0.47 – $0.88
52-Week Range
$0.28 – $4.99
Volume
$1.26M
Market Cap
$17.62M
50-Day Avg
$0.66
200-Day Avg
$0.87
Prev Close
$0.54
Open
$0.86

Valuation & Ratios

P/E Ratio
-0.53
EPS
$-1.41
P/B Ratio
1.48
P/S Ratio
0.00
Debt/Equity
0.01
Current Ratio
3.30
Dividend Yield
+0.0%
Gross Margin
+0.0%

Returns & Efficiency

Return on Equity
-279.3%
Return on Assets
-197.5%
FCF Yield
-144.8%
EV/EBITDA
-0.44

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$0.00$-55.92M$-1.41
2024$0.00$-26.57M$-0.73
2023$0.00$-37.64M$-5.37
2022$0.00$-19.48M$-8.77
2021$0.00$-8.52M$-5.00

Social Signal Score

41
5d
41
2 mentions
—
30d
41
2 mentions
—
60d
41
2 mentions
—
90d
41
2 mentions
—
news: 2

Earnings

Mon, Nov 9(in 3 months)

Consensus estimate $-0.24 per share

3of 7 quarters beat consensus

Typical surprise -5.9% (median, so one quarter with a near-zero estimate can't distort it)

  • Fri, Aug 14$-0.27 vs $-0.25miss
  • Mon, May 11$-0.32 vs $-0.29miss
  • Tue, Mar 10$-0.36 vs $-0.30miss
  • Mon, Nov 10$-0.32 vs $-0.33beat
  • Thu, Aug 7$-0.44 vs $-0.34miss
  • Thu, May 8$-0.28 vs $-0.31beat

Estimates and results for SKYE via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Valuation

SKYEhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (2)

  • Newsseekingalpha.com·22h ago·Neutral

    Skye Bioscience, Inc. (SKYE) M&A Call Prepared Remarks Transcript Skye Bioscience, Inc. (SKYE) M&A Call Prepared Remarks Transcript

    View source ↗
  • Newsglobenewswire.com·1d ago·Negative

    …nference call on August 14, 2026 at 10 a.m. ET SAN DIEGO and ALDERLEY PARK, United Kingdom, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (“Skye”) (Nasdaq: SKYE), and Redx Pharma Limited (“Redx”), a U.K. based, privately-held clinical-stage biotechnology company focused on developing novel, small molecule, targeted medicines for fibrotic disease, today announced that they have entered into a definitive transaction agreement (the “Transaction Agreement”).

    View source ↗